Mari Andrea, Kimura Shoji, Foerster Beat, Abufaraj Mohammad, D'Andrea David, Gust Kilian M, Shariat Shahrokh F
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, University of Florence, Careggi Hospital, Florence, Italy.
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria; Department of Urology, Jikei University School of Medicine, Tokyo, Japan.
Urol Oncol. 2018 Jun;36(6):293-305. doi: 10.1016/j.urolonc.2018.03.018. Epub 2018 Apr 21.
Lymphovascular invasion (LVI) is an important step in bladder cancer cell dissemination. We aimed to perform a systematic review and meta-analysis of the literature to assess the prognostic value of LVI in radical cystectomy (RC) specimens.
A systematic review and meta-analysis of the last 10 years was performed using the MEDLINE, EMBASE, and the Cochrane libraries in July 2017. The analyses were performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISMA) statement.
We retrieved 65 studies (including 78,107 patients) evaluating the effect of LVI on oncologic outcomes in patients treated with RC. LVI was reported in 35.4% of patients. LVI was associated with disease recurrence (pooled hazard ratio [HR] = 1.57; 95% CI: 1.45-1.70) and cancer-specific mortality (CSM) (pooled HR = 1.59; 95% CI: 1.48-1.73) in all studies regardless of tumor stage and node status (pT1-4 pN0-2). LVI was associated with recurrence and CSM in patients with node-negative bladder cancer (BC). In patients with node-negative BC, LVI rate increased and was associated with worse oncologic outcome. LVI had a lower but still significant association with disease recurrence and CSM in node-positive BC.
LVI is a strong prognostic factor of worse prognosis in patients treated with RC for bladder cancer. This association is strongest in node-negative BC, but it is also in node-positive BC. LVI should be part of all pathological reporting and could provide additional information for treatment-decision making regarding adjuvant therapy after RC.
淋巴管浸润(LVI)是膀胱癌细胞播散的重要步骤。我们旨在对文献进行系统评价和荟萃分析,以评估LVI在根治性膀胱切除术(RC)标本中的预后价值。
2017年7月使用MEDLINE、EMBASE和Cochrane图书馆对过去10年进行了系统评价和荟萃分析。分析按照系统评价和荟萃分析的首选报告项目(PRISMA)声明进行。
我们检索了65项研究(包括78107例患者),评估LVI对接受RC治疗患者肿瘤学结局的影响。35.4%的患者报告有LVI。在所有研究中,无论肿瘤分期和淋巴结状态(pT1-4 pN0-2)如何,LVI均与疾病复发(合并风险比[HR]=1.57;95%可信区间:1.45-1.70)和癌症特异性死亡率(CSM)(合并HR=1.59;95%可信区间:1.48-1.73)相关。LVI与淋巴结阴性膀胱癌(BC)患者的复发和CSM相关。在淋巴结阴性的BC患者中,LVI发生率增加且与更差的肿瘤学结局相关。在淋巴结阳性的BC患者中,LVI与疾病复发和CSM的相关性较低但仍具有统计学意义。
LVI是接受RC治疗的膀胱癌患者预后较差的一个强有力的预后因素。这种关联在淋巴结阴性的BC患者中最强,但在淋巴结阳性的BC患者中也存在。LVI应成为所有病理报告的一部分,并可为RC术后辅助治疗的治疗决策提供额外信息。